Target intelligence / Profile preview

Cellular RNA substrates incidentally edited by TadA*7.10 (ABE7.10 RNA off-targets)

Target
ABE7.10 RNA off-targets
Molecular classification
RNA, Nucleic acid
01

Overview

Cellular RNA substrates incidentally edited by TadA*7.10 refer to the vast array of messenger RNA (mRNA) and other RNA transcripts that undergo unintended adenosine-to-inosine (A-to-I) deamination when the Adenine Base Editor 7.10 (ABE7.10) is present in a cell (Grünewald et al., 2019, Nature). TadA*7.10 is an evolved version of the Escherichia coli tRNA adenosine deaminase enzyme, engineered to edit DNA but retaining a high affinity for RNA (Gaudelli et al., 2017, Nature). Research has shown that ABE7.10 can cause thousands of off-target RNA edits across the transcriptome, which are independent of the DNA-targeting guide RNA (Zhou et al., 2019, Nature). These incidental edits can lead to the translation of mutant proteins or altered RNA stability, posing a significant safety concern for the clinical application of base editing technologies. While newer generations of base editors, such as ABE8e or SECURE-ABEs, have been developed to minimize these effects, the RNA substrates of TadA*7.10 remain a critical benchmark for evaluating the specificity and safety of genome editing tools. Monitoring these substrates is essential for ensuring that therapeutic base editing does not induce systemic proteomic instability or unintended phenotypic changes.

Other names
Transcriptome-wide RNA off-targets of ABE7.10TadA*7.10-mediated RNA editingABE-induced RNA deaminationIncidental RNA substrates of adenine base editors
02

Mechanism of action

The TadA*7.10 subunit of the ABE7.10 base editor catalyzes the hydrolytic deamination of adenosine to inosine (A-to-I) in cellular RNA transcripts, which are then interpreted as guanosine by the translation machinery (Grünewald et al., 2019; Zhou et al., 2019).

03

Biological functions

Post-transcriptional RNA modificationAdenosine deamination
04

Disease associations

Off-target toxicityProteotoxicity
05

Safety considerations

Transcriptome-wide off-target mutationsProduction of deleterious protein variantsPotential for cellular toxicityUnintended phenotypic changes
06

Interacting drugs

Adenine Base Editor 7.10 (ABE7.10)
07

Biomarkers

RNA-seq (Transcriptome-wide sequencing)A-to-I editing frequency

Beyond the preview

Go deeper on Cellular RNA substrates incidentally edited by TadA*7.10 (ABE7.10 RNA off-targets).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cellular RNA substrates incidentally edited by TadA*7.10 (ABE7.10 RNA off-targets).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call